| Cholangiocarcinoma
Pemazyre vs Tibsovo
Side-by-side clinical, coverage, and cost comparison for cholangiocarcinoma.Deep comparison between: Pemazyre vs Tibsovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTibsovo has a higher rate of injection site reactions vs Pemazyre based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tibsovo but not Pemazyre, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Pemazyre
Tibsovo
At A Glance
Oral
Once daily
FGFR1-3 inhibitor
Oral
Daily
IDH1 inhibitor
Indications
- Cholangiocarcinoma
- Myeloid/lymphoid neoplasm
- Leukemia, Myelocytic, Acute
- MYELODYSPLASTIC SYNDROME
- Cholangiocarcinoma
Dosing
Cholangiocarcinoma 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cycles; continue until disease progression or unacceptable toxicity.
Myeloid/lymphoid neoplasm 13.5 mg orally once daily on a continuous basis; continue until disease progression or unacceptable toxicity.
Leukemia, Myelocytic, Acute 500 mg orally once daily; newly diagnosed: in combination with azacitidine 75 mg/m2 SC or IV on Days 1-7 of each 28-day cycle, or as monotherapy, for minimum 6 months; relapsed/refractory: monotherapy until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME 500 mg orally once daily as monotherapy until disease progression or unacceptable toxicity; continue for minimum 6 months.
Cholangiocarcinoma 500 mg orally once daily until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) Hyperphosphatemia, alopecia, nail toxicity, diarrhea, fatigue, nausea, stomatitis, dry eye, dry mouth, constipation, decreased appetite, dysgeusia, arthralgia, abdominal pain, hypophosphatemia, vomiting, back pain, dry skin, edema peripheral, rash, anemia, epistaxis
Serious Abdominal pain, pyrexia, cholangitis, pleural effusion, acute kidney injury, cholangitis infective, failure to thrive, hypercalcemia, hyponatremia, small intestinal obstruction, urinary tract infection
Most common (>=25%) leukocytes decreased, diarrhea, hemoglobin decreased, platelets decreased, glucose increased, fatigue, alkaline phosphatase increased, edema, potassium decreased, nausea, vomiting, phosphatase decreased, decreased appetite, sodium decreased, leukocytosis, magnesium decreased, aspartate aminotransferase increased, arthralgia, dyspnea, uric acid increased, abdominal pain, creatinine increased, mucositis, rash, electrocardiogram QT prolonged, differentiation syndrome, calcium decreased, neutrophils decreased, myalgia
Serious differentiation syndrome, electrocardiogram QT prolonged, leukocytosis, Guillain-Barre syndrome
Pharmacology
Pemigatinib is a selective small molecule inhibitor of fibroblast growth factor receptors 1, 2, and 3 (FGFR1-3) that blocks receptor phosphorylation and downstream signaling, inhibiting proliferation of cancer cells harboring activating FGFR amplifications, fusions, or rearrangements.
Ivosidenib is a small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme that reduces 2-hydroxyglutarate (2-HG) levels and induces myeloid differentiation in IDH1-mutated AML; in IDH1-mutated cholangiocarcinoma, it also reduces 2-HG levels in tumor tissue.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Pemazyre
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tibsovo
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (4/12) · Qty limit (12/12)
UnitedHealthcare
Pemazyre
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Tibsovo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Pemazyre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tibsovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Biliary Tract Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tibsovo.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PemazyreView full Pemazyre profile
TibsovoView full Tibsovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.